Septerna (SEPN) Non Operating Income (2023 - 2026)
Septerna's quarterly Non Operating Income came in at $5.0 million in Q1 2026, up 17957.14% year-on-year from N/an in Q1 2025, and down 74.34% quarter-over-quarter from $19.5 million in Q4 2025.
Septerna has reported Non Operating Income for 4 years, with the latest figure at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 17957.14% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 251.27% YoY), and the FY2025 full-year result was $19.4 million, up 127.86% from the prior year.
- Non Operating Income for Q1 2026 stood at $5.0 million, down from $19.5 million in the prior quarter.
- The five-year high for Non Operating Income was $19.5 million in Q4 2025, with the low at -$1.5 million in Q4 2023.
- Average Non Operating Income over 4 years is $3.6 million, with a median of $1.1 million recorded in 2023.
- Peak annual rise in Non Operating Income reached 61866.67% in 2025, while the deepest fall reached 102.27% in 2025.
- Tracing SEPN's Non Operating Income over 4 years: stood at -$1.5 million in 2023, then soared by 666.47% to $8.6 million in 2024, then surged by 126.64% to $19.5 million in 2025, then sank by 74.34% to $5.0 million in 2026.
- The last three Non Operating Income figures came in at $5.0 million (Q1 2026), $19.5 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.00 Mn |
| Dec 31, 2025 | 19.49 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Jun 30, 2025 | -25,000.00 |
| Mar 31, 2025 | -28,000.00 |
| Dec 31, 2024 | 8.60 Mn |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | -1.52 Mn |
| Sep 30, 2023 | 1.10 Mn |